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Abstract 
Patient-derived xenograft (PDX) models are effective preclinical cancer models that reproduce the 
tumor microenvironment of the human body. The methods have been widely used for drug screening, 
biomarker development, co-clinical trials, and personalized medicine. However, the low success rate and 
the long tumorigenesis period have largely limited their usage. In the present studies, we compared the 
PDX establishment between hepatocellular cancer (HCC) and metastatic liver cancer (MLC), and 
identified the key factors affecting the transplantation rate of PDXs. Surgically resected tumor specimens 
obtained from patients were subcutaneously inoculated into immunodeficient mice to construct PDX 
models. The overall transplantation rate was 38.5% (20/52), with the HCC group (28.1%, 9/32) being 
lower than MLC group (56.2%, 9/16). In addition, HCC group took significantly longer latency period than 
MLC group to construct PDX models. Hematoxylin and eosin staining results showed that the 
histopathology of all generations in PDX models was similar to the original tumor in all three types of 
cancer. The transplantation rate of PDX models in HCC patients was significantly associated with blood 
type (P=0.001), TNM stage (P=0.023), lymph node metastasis (P=0.042) and peripheral blood CA19-9 
level (P=0.049), while the transplantation rate of PDX models in MLC patients was significantly associated 
with tumor size (P=0.034). This study demonstrates that PDX models can effectively reproduce the 
histological patterns of human tumors. The transplantation rate depends on the type of original tumor. 
Furthermore, it shows that the invasiveness of the original liver cancer affects the possibility of its growth 
in immunodeficient mice. 
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Introduction 
Liver cancer can be divided into two major 
categories: primary liver cancer (PLC), which arises 
from the liver, and secondary liver cancer, also known 
as metastatic liver cancer (MLC), which is formed 
initially from other parts of the body and then spreads 
to the liver. Hepatocellular carcinoma (HCC), the 
major type of PLC, is the fourth most common cause 
of cancer-related death worldwide [1]. Liver cancer 
management includes surgery, chemotherapy, 
ablation therapy and targeted medicine treatment. 
Although surgery is the most effective treatment, a 
large number of patients missed the surgery 
opportunity when diagnosed. Many of these patients 
with unresectable HCC or MLC have to take the 
multi-kinase inhibitor Sorafenib as alternative 








adverse effects that might be harmful for patients’ 
wellbeing [2, 3]. The quest for an optimized, well- 
tolerated, minimally invasive, cost-effective therapy 
for liver cancer management remains an unmet 
clinical need and active research topic. Therefore, 
relevant preclinical animal models are crucial for the 
development of innovative approaches for liver 
cancer therapy, such as gene therapy and 
immunotherapy. 
Patient-derived xenograft (PDX) models have 
been commonly used for developing new drugs and 
guiding individualized medicine [4]. PDX models are 
established by subcutaneously or orthotopically 
transplanting tumor tissues of patients into immuno-
deficient mice such as NOD/SCID (non-obese 
diabetic/severe combined immunodeficiency) mice, 
which can reproduce the tumor microenvironment 
similar to primary tumors in human bodies [5-8]. 
PDXs of various tumors have been constructed, such 
as colorectal cancer [9], breast cancer [10], and renal 
cell carcinoma [11] over the last few years. In our 
previous study, we have revealed the PDXs of 
pancreatic cancer could well recapitulated the 
histologic, expression and biological characteristics of 
the corresponding primary tumors [12]. However, the 
low success rate, long tumorigenesis period and high 
cost are huge obstacles limiting the widespread of 
PDXs in clinical treatment. Therefore, how to solve 
these problems and make transplant easier to operate 
remain our task in the long research path. In this 
study, we focus on the difference of patient-derived 
xenograft models in hepatocellular carcinoma and 
metastatic liver cancer, in hope that the findings can 
provide useful message for improving the success rate 
of PDX. 
Material and Methods 
Patients and samples 
Surgically resected tumor specimens (n=52) and 
paired adjacent normal tissues were obtained from 
patients diagnosed with HCC, MLC or CRC, who 
underwent surgery at the Peking University Cancer 
Hospital from November 2013 to January 2014. Each 
specimen measured approximately 1×1×1 cm in 
dimension. Fresh tumor specimens were divided into 
three parts: one part was transferred to antibiotic- 
containing Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco BRL, Life Technologies, Grand Island, 
NY, USA) for tumor transplantation; one part was 
fixed in 4% formalin for Hematoxylin-eosin (H&E) 
staining; and the rest was immediately transferred to 
liquid nitrogen and stored at -80°C for future studies. 
Each part measured approximately 5×5×5 mm. This 
study was approved by the medical ethics committee 
of Peking University Cancer Hospital and was carried 
out in accordance with the approved guidelines. 
Establishment of PDX models 
All tumor specimens from the patients (termed 
F0) were subcutaneously inoculated into the right 
buttock of 5-week-old NOD/SCID mice (Beijing HFK 
Bio-Technology Co., LTD, Beijing, China), weighting 
18-20 g. Tumor specimens were cut into small pieces 
(less than 1 mm3) and mixed with Matrigel (100 µl per 
sample) (BD Biosciences, Heidelberg, Germany) for 20 
seconds at room temperature, immediately prior to 
xenotransplantation. Tumor growth was measured 
twice a week by a Vernier caliper, using the following 
formula [13]: tumor volume = (length×width2)/2. 
When the tumor size reached approximately 
1000 mm3, the xenograft mouse was sacrificed under 
anesthesia, and the tumor was excised and divided 
into three parts, identical to the procedure followed 
for the human specimens. The DMEM-stored portion 
was used to re-inoculate the mice to obtain 
subsequent generations containing the tumor mass. 
This generation of mice, receiving the patient tumor 
transplant, was termed F1. Similarly, the following 
generations were termed F2, F3…Fn respectively [14]. 
Mice were kept in the animal facilities of the Peking 
University Cancer Hospital and maintained in 
specified pathogen-free conditions. Animals were 
exposed to 12 h light/12 h darkness cycles and 
provided with standard food and water ad libitum. 
All procedures were performed under sterile 
conditions and carried out in accordance with the 
Guide for the Care and Use of Laboratory Animals of 
the National Institutes of Health. 
Statistical analysis 
The sample size of this study was determined 
using R [R Core Team (2019), Version 3.6.1] with 
RStudio (Version 1.2.5019) and Pwr Package prior to 
commencing the experiment with a view of obtaining 
a power of 80%. Calculation was based on the lines of 
Cohen (1988) using in particular the same notations 
for effect sizes [15]. The estimated sample size needed 
to reach 80% power on the 0.05 significance level 
(two-sided test) with a correlation coefficient (r) 
smaller than 0.5, leaded to a sample size of 28 study 
subjects. 
Unpaired 2-tailed t tests were used for group 
comparisons after verifying normality and 
homogeneity of variance. The relationship between 
clinicopathological characteristics and transplantation 
rate of xenografts was analyzed using the chi-square 
test (all patients when more than 40 samples were 
enrolled) and Fisher’s exact test (HCC and MLC 
patients when less than 40 samples were enrolled). All 




statistical analyses were performed using IBM SPSS 
25.0 software (SPSS Inc., Chicago, IL, USA). 
In addition, all patients were evaluated for 
overall survival (OS) and progression-free survival 
(PFS). OS was defined as the elapsed time between the 
inclusion date and death due to any cause. PFS was 
defined as the elapsed time between the date of 
inclusion and the date of tumor progression. During 
the study, all patients did not die within 30 days of 
surgery. GraphPad Prism (version 7.0) was used to 
produce Kaplan-Meier survival curves and log-rank 
test was used to estimate the differences in both OS 
and PFS analyses. P values less than 0.05 (p<0.05) 
were considered to be statistically significant. 
Results 
Comparison of PDXs transplantation rates 
and latency period among different types of 
xenografted tumors 
During the course of the study, a total of 80 
generations of PDXs have been produced with 52 
individual patient tumors, 20 (38.5%) of which were 
successfully generated and obtained as first 
generation of PDXs (F1). Transplantation rate of HCC 
(28.1%) was the lowest compared with CRC (50.0%) 
and MLC (56.2%) (Table 1). Compared with MLC 
group, HCC group displayed a significantly longer 
latency period (Table 1). In addition, successful 
engraftment of F2 PDXs took significant less time than 
F1 PDXs in MLC group, which was consistent with 
our previous finding in pancreatic cancer study [12]. 
However, the latency period results did not show 
significant differences between F1 and F2 PDXs in the 
whole group. 
 
Table 1. Primary and secondary engraftment outcomes for all 
tumor types  
Tumor histologic type All tumor 
types (n=52) 
CRC (n=4) HCC(n=32) MLC (n=16) 
F1 engraftment results    
No growth 32 (61.5%) 2 (50%) 23 (71.9%) 7 (43.8%) 
Success 20 (38.5%) 2 (50%) 9 (28.1%) 9 (56.2%) 
Latency period, days 67.7±34.1 45±12.7 88.2±34.9* 52.2±25.4 
F2 engraftment results    
No growth 7 (43.8%) 0 (0%) 5 (83.3%) 1 (12.5%) 
Success 9 (56.2%) 2 (100%) 1 (16.7%) 7 (87.5%) 
Latency period, days 45.0±19.6 66.5±36.1 34±0.0 38.9±9.8# 
CRC, colorectal carcinoma; HCC, hepatocellular carcinoma; MLC, metastatic liver 
cancer; 
*p<0.05 compared with MLC group. #p<0.05 compared with F1 PDXs group. 
 
Comparison of histopathological 
characteristics 
H&E staining was performed to compare the 
histopathology between patient tumor and its mouse 
avatar models. Differentiation was judged by two 
independent pathologists. The results showed that 
both F1 and F2 PDXs could preserve tumor 




Figure 1. PDX generation in original tumors and NOD/SCID mice. Representative H&E staining results of tumors from HCC, MLC and CRC patients and their two 
corresponding passages of xenografts (×200). Pathological features of tumor could be conserved within two generations of passage in immunodeficient mice (F0 represents 
tumor from patient, F1 and F2 represent tumor from PDX line). 





Table 2. Correlations between transplantation rate and 
clinicopathological parameters of all patients 





Gender   0.404 
Female 10 (19.2%) 5 (50.0%)  
Male 42 (80.8%) 15 (35.7%)  
Age (years)   0.264 
<60 31 (59.6%) 10 (32.3%)  
≥60 21 (40.4%) 10 (47.6%)  
Tumor type   0.079 
Primary tumor (HCC and CRC) 36 (69.2%) 11 (30.6%)  
MLC 16 (30.8%) 9 (56.3%)  
Smoking history   0.350 
No 35 (67.3%) 15 (42.9%)  
Yes 17 (32.7%) 5 (29.4%)  
History of alcohol consumption   1.000 
No 39 (75.0%) 15 (38.5%)  
Yes 13 (25.0%) 5 (38.5%)  
Tumor size (cm)   0.143 
<5.2 30 (57.7%) 9 (30.0%)  
≥5.2 22 (42.3%) 11 (50.0%)  
Blood type   0.008** 
O 13 (25.0%) 9 (69.2%)  
Non-O (A, B, and AB) 39 (76.0%) 11 (28.2%)  
Vascular invasion   0.924 
No 36 (69.2%) 14 (38.9%)  
Yes 16 (30.8%) 6 (37.5%)  
Perineuronal invasion   1.000 
No 30 (57.7%) 10 (33.3%)  
Yes 3 (5.8%) 1 (33.3%)  
NA 19 (11.5%) 9 (47.4%)  
Differentiation   0.583 
Moderate 32 (61.6%) 11 (34.4%)  
Poor 14 (26.9%) 6 (42.9%)  
NA 6 (11.5%) 3 (50.0%)  
TNM stage   0.008** 
I-II 25 (48.1%) 5 (20.0%)  
III-IV 27 (51.9%) 15 (55.6%)  
Lymph node metastasis   0.120 
Present 17 (32.7%) 9 (52.9%)  
Absent 30 (57.7%) 9 (30.0%)  
NA 5 (9.6%) 2 (40.0%)  
Distant metastasis   0.102 
Present 17 (32.7%) 9 (52.9%)  
Absent 31 (59.6%) 9 (29.0%)  
NA 4 (7.7%) 2 (50.0%)  
CEA (0-5 ng/ml)   0.015* 
Normal 34 (65.4%) 9 (26.5%)  
Abnormal 18 (34.6%) 11 (61.1%)  
CA19-9 (0-37 U/ml)   0.017* 
Normal 29 (55.8%) 7 (24.1%)  
Abnormal 23 (44.2%) 13 (56.5%)  
CA72.4 (0-6.7 U/ml)   0.264 
Normal 31 (59.6%) 13 (41.9%)  
Abnormal 21 (40.4%) 7 (33.3%)  
CA242 (0-20 U/ml)   0.135 
Normal 35 (67.3%) 11 (31.4%)  
Abnormal 17 (32.7%) 9 (52.9%)  
CRC, colorectal carcinoma; HCC, hepatocellular carcinoma; MLC, metastatic liver 
cancer; NA, not available; 
*p<0.05, **p<0.01. Chi-square test. 
 
Correlation between transplantation rate of 
F1 PDXs and clinicopathological 
characteristics 
Our results showed that the transplantation rate 
of PDXs was statistically significant associated with 
blood type (P=0.008), TNM stage (P=0.008), 
peripheral blood CEA (P=0.015) and CA19-9 level 
(P=0.017) when total patients were enrolled in the 
statistical analysis (Table 2). 
Results of HCC patients showed that the 
transplantation rate of PDXs was statistically 
significant associated with blood type (P=0.001), TNM 
stage (P=0.023), lymph node metastasis (P=0.042) and 
peripheral blood CA19-9 level (P=0.049) (Table S1 and 
Figure 2). 
Results of MLC patients showed that the 
transplantation rate of PDXs was statistically 
significant associated with tumor size (P=0.034) (Table 
S2 and Figure 2). 
Furthermore, we analyzed the correlations 
between transplantation rate of PDXs and HBV- 
related antigen/antibody of HCC patients. The results 
showed that there were no statistically significant 
correlations between transplantation rate of F1 PDXs 
and any of the HBV-related antigens or antibodies 
(Table S3), which were consistent with the result of 
history of hepatitis virus infection (Table S1). 
Survival analysis 
During the diligent follow-up of more than five 
years, the median follow-up time was 551 days 
(range: 44-1829 days) for deceased patients and 1795 
days (range: 96-1988 days) for patients still alive after 
follow-up study. The median OS in all of the 52 
patients was 1829 days (range: 44-1988 days). OS 
results showed that there was no significant 
difference between the median OS in patients with 
successful F1 PDX transplantation and patients with 
failed F1 PDXs (P=0.3155), Figure 3A. Similar result 
was found in MLC patients, (P=0.1701) Figure 3C. 
However, the median OS in patients with failed F1 
PDXs transplantation was significantly superior to 
those with successful F1 PDX transplantation, 
(P=0.0428) Figure 3B. 
PFS results showed significant differences 
between patients with successful and failed F1 PDX 
transplantation, both in total and HCC patients 
(P=0.0269, P=0.0103, respectively) Figure 3A and B, 
respectively. However, no detectable difference was 
found in MLC patients, (P=0.4050) Figure 3C. 
Discussion 
To thoroughly understand liver cancer and its 
translation into effective treatment, it is essential to 
establish an appropriate human preclinical model to 
capture the heterogeneity of cancer. Most of the 
tumors in liver cancer animal models are from 
drug-induced liver cancer or human cancer cell line 
derived animal models currently. However, the main 




drawback of these animal models is lack of both 
phenotypic and genetic heterogeneity found in the 
original tumors [16]. Importantly, cancers consist of a 
continuously evolving heterogeneous cell mass and 
not all cells within a tumor contribute equally to their 
progression [17]. Therefore, animal models possessing 
the characteristic of patient tumors that could 
accurately mimic human cancers are urgently needed 
in cancer research. Surgically derived primary clinical 
tumor samples can be grafted into immunodeficiency 
mice to construct PDX models. In such models, tumor 
architecture and the relative proportion of cancer cells 
and stromal cells are maintained to a large extent, 
which yield better resemblance to the original tumors 
[16, 18]. In our study, the successful engraftment rate 
of F1 PDXs of all samples was 38.5%, which is slightly 
lower than the reported previously around 40%-60% 
[19-22], which was attributed to the lowest successful 
engraftment rate of HCC samples (28.1%). In addition, 
it took longer latency period of time to establish F1 
PDXs of HCC than other tumor types. Furthermore, 
successful engraftment rate of F2 PDXs of HCC was 
also lower than CRC and MLC. These results revealed 
that the engraftment rate of PDXs was different 
according to implanted tumor types. PDX models are 
currently established in variety of cancers, including 
colorectal [23], pancreatic [24], breast [25], lung [26], 
prostate [27] and ovarian cancer [28]. However, 
reports about PDX models of HCC were rare. 
Recently a study reported a 20% successful 
engraftment rate in a cohort sample of 14 HCC 
patients [29], another study with a larger sample size 
reported that only 11 successfully engrafted from 54 
human HCC needle biopsies [30]. The overall success 
rate of HCC in our study was slightly higher than 
researchers reported before. 
 
 
Figure 2. The correlations between transplantation rate and clinicopathological parameters. (A) Tumor size, (B) blood type, (C) TNM stage, (D) lymph node metastasis, (E) 
CEA and (F) CA19-9 level. The transplantation rate of HCC xenografts was statistically significant associated with blood type, TNM stage, lymph node metastasis and peripheral 
blood CA19-9 level. The transplantation rate of MLC xenografts was statistically with tumor size. * represents p<0.05, ** represents p<0.01. 





Figure 3. OS and PFS in relation to transplantation status of patients. (A) OS (left) and PFS (right) of all patients with and without success engraftment; (B) OS (left) and PFS 
(right) of HCC patients with and without success engraftment; (C) OS (left) and PFS (right) of MLC patients with and without success engraftment. Log-rank p-values are shown 
in each of the result. 
 
Comparison of H&E staining results showed 
that PDXs could reproduce the histological 
morphology and pathology of all types of tumor 
(Figure 1). In our previous study, we found PDX lines 
could preserve the histological characters of 
pancreatic cancer from patients within at least three 
generations [12]. Only two generations were 
established in this study, while all F2 PDXs showed 
well recapitulate the histological characters of their 
original tumors. Therefore, we assume that PDX 
models could resemble the histological characters of 
various primary tumors during passage in PDX lines.  
Back to 1953, a hall mark study by Helene Toolan 
demonstrated that tumor xenografts were possible to 
establish in immune repressed hosts [31]. After nearly 
20 years, researchers found that anti-lymphocyte 
serum could improve the percentage of viable 
patient-derived tumor grafts slightly [32]. Following 
these studies, researchers managed to construct 
severely immunodeficient mice such as the non-obese 
diabetic/severe combined immunodeficiency 
(NOD/SCID) mice, which homozygous for the severe 
combined immune deficiency spontaneous mutation 
(Prkdcscid, commonly referred to as scid) with 
NOD/ShiLtSz background. NOD/SCID mice are 
characterized by an absence of functional B and T 
cells, lymphopenia, hypogammaglobulinemia, and a 
normal hematopoietic microenvironment, normal 
antigen-presenting cell, myeloid, and natural killer 
(NK) cell functions are also extremely low [33, 34]. 
“Leak” or scid leakiness – mice that have serum Ig 
levels greater than 1 µg/ml – is highly strain 
dependent, increases with age, and is higher in mice 
housed under non-SPF (specified pathogen free) 




conditions [35, 36]. NOD/ShiLtSz strain has the 
lowest scid leakiness rate among several common 
genetic backgrounds such as C57BL/6J, BALB/cBy, 
C3H/HeJ and NOD/ShiLtSz [37]. In this study, 
young mice (weighting 18-20g) were selected and 
raised in an SPF condition under strict sterile 
procedure to avoid leakiness to the great extent. 
Absence of immune system in these mice allows 
for higher engraftment rates. Although successful 
engraftment rate has been remarkably improved by 
applying severely immune deficient mice, there are 
still a great number of the patient tumors that couldn’t 
grow in mice [22, 29, 38]. To provide useful evidence 
for improving engraftment rates, the influencing 
factors of engraftment rate were carefully investigated 
in our study. In this study, transplantation rate was 
significantly related to blood type, TNM stage, CEA 
and CA19-9 level in the whole cohort of patients 
(Figure 2, Table 2). TNM stage, CEA and CA19-9 are 
associated with malignant degree of tumor [39, 40]. 
These results showed that the invasiveness of the 
original tumor affects the possibility of its growth in 
immunodeficient mice. The fact that transplantation 
rate of MLC was higher than HCC may also 
confirmed this conclusion. In the cohort of HCC 
patients, the factors associated with aggressive degree 
such as TNM stage, lymph node metastasis and 
CA19-9 level, were similar with the results found in 
whole cohort of patients. Furthermore, failed-PDX 
donors of HCC patients had a favorable prognosis 
compared with successful-PDX donors. The survival 
analysis results further validate the fact that the 
invasiveness of the original tumor affects the 
possibility of its growth in immunodeficient mice. 
Although PDX models are frequently used for cancer 
research, few studies have reported relevant clinical 
factors that may affect transplantation rate. Therefore, 
it is very important to reveal clinicopathological 
parameters that may relate to PDX transplantation 
rate. 
To our surprise, patients with blood type O were 
more easily to grow their tumors in mice avatars 
(whole, p=0.008, Table 2; HCC, p=0.001, Table S1; 
MLC, p=0.585, Table S2; Figure 2). The ABO blood 
group has been found to be associated with the risk of 
multiple malignancies, including gastrointestinal tract 
cancers [41] and liver cancer[42]. The ABO gene is 
located on chromosome 9q34 encoding several 
glycosyl transferases that add sugar residues to the 
H(O) antigen to form ABO antigens. An association 
between polymorphisms at the ABO gene locus and 
circulating levels of several important adhesion 
molecules such as soluble intercellular adhesion 
molecule (ICAM)-1 and tumor necrosis factor-alpha 
was reported previously [43, 44]. Researchers found 
that the expression of soluble ICAM-1 was 
significantly reduced in patients with non-O blood 
group compared to the expression in those with blood 
group O. The decreased soluble ICAM levels in 
patients may promote metastatic spread of tumors, 
therefore related with a poor prognosis [45]. Although 
those researches demonstrated there may be 
differences among ABO blood groups, the exact 
underlying mechanism by which ABO blood group 
influence tumorigenesis and development remains 
unclear. Additional experimental studies are needed 
to unravel the pathogenic mechanisms linking ABO 
blood types with transplantation rate. 
Although PDX models recapitulate tumor tissue 
more closely than cancer cell lines, they are usually 
generated from a small amount of primary tumor. The 
limitation of grafts could not capture the full 
heterogeneity of the original tumor [46]. Another 
limitation of this study is that the immuno-
histochemical (IHC) study was not applied. We 
observed not more than one kind of cancer, the 
primary tumors of MLC also consisted with several 
tumor types. The pathological features of various 
types of tumors are different from each other. 
Therefore, only comparison of pathological pattern 
through H&E staining method was designed prior to 
our experiments. We will check the expression 
patterns of key factors by multiple detection methods 
such as IHC, real-time PCR and high-throughput 
sequencing in the following study. Furthermore, 
sample size of our study was relatively small and only 
two generations of PDXs were studied in this 
research, we will construct more mice avatar models 
and studied more generations of PDX lines in the 
future to get more in-depth data. Nevertheless, our 
research provides a comprehensive and objective 
basis for the study of PDX. 
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